| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.3 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.052 | 0.3 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.059 | 0.3 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |